

LA RADIOTERAPIA NEL CARCINOMA DEL CANALE ANALE:
INDICAZIONI E CRITERI GUIDA DI TRATTAMENTO

Rionero in Vulture, 31 ottobre 2014

Corso itinerante AIRO

IL RUOLO DELLA BRACHITERAPIA



Luca TAGLIAFERRI

RADIOTERAPIA ONCOLOGICA - GEMELLI-ART

Policlinico Agostino Gemelli - Università Cattolica del Sacro Cuore - Roma

LINEE-GUIDA

Radiotherapy and Oncology 111 (2014) 330–339

Contents lists available at [ScienceDirect](#)

 **ELSEVIER**

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



Guidelines

Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up [☆]


 CrossMark

Robert Glynne-Jones ^a, Per J. Nilsson ^b, Carlo Aschele ^c, Vicky Goh ^d, Didier Peiffert ^e, Andrés Cervantes ^f, Dirk Arnold ^{g,*}

^a Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, United Kingdom; ^b Department of Molecular Medicine and Surgery, Karolinska Institutet and Center for Surgical Gastroenterology, Karolinska University Hospital, Stockholm, Sweden; ^c Medical Oncology and Hematology, Felettino Hospital, La Spezia, Italy; ^d Division of Imaging Sciences & Biomedical Engineering, King's College London, United Kingdom; ^e Radiotherapy Department, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France; ^f Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Spain; ^g Klinik für Tumorbologie, Freiburg, Germany


- Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D. - Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. - **Radiother Oncol. 2014**

LINEE-GUIDA



- Glynn-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D. - Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. - **Radiother Oncol. 2014**


LINEE-GUIDA



- Glynn-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D. - Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. - **Radiother Oncol. 2014**

The Rise and Fall of Prostate Brachytherapy: Use of Brachytherapy for the Treatment of Localized Prostate Cancer in the National Cancer Data Base

Jeffrey M. Martin, MD, MS¹; Elizabeth A. Handorf, PhD²; Alexander Kutikov, MD³; Robert G. Uzzo, MD³; Justin E. Bekelman, MD⁴; Eric M. Horwitz, MD¹; and Marc C. Smaldone, MD, MSHP³




- Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. **Cancer**. 2014

Problematiche della BT

- Problematiche radio-protezionistiche
- Necessità di una sala operatoria/bunker dedicato
- Equipe specializzata in brachiterapia
- Rimborsi minori rispetto ad altre metodiche (es. IMRT)
- Costi maggiori
 - cateteri
 - sorgenti radioattive
 - gestione sala operatoria
- Degenza (impianto interstiziale)
- Rischio di sanguinamento/infezione




Carcinoma del canale anale: controllo locale e sopravvivenza



Vantaggi della BT

- Possibilità di prescrivere una dose maggiore al target
- Possibilità di collimare la dose (IMBT)
- Minore dose agli organi a rischio (rapid fall off)
- Corto Overall Treatment Time (OTT)



Boost: ERT o BT

CLINICAL INVESTIGATION

Anus

HIGH-DOSE SPLIT-COURSE RADIATION THERAPY FOR ANAL CANCER: OUTCOME ANALYSIS REGARDING THE BOOST STRATEGY (CORS-03 STUDY)

JEAN-MICHEL HANNOUN-LEVI, M.D., PH.D.,^{*††} CÉCILE ORTHOLAN, M.D.,^{*} MICHEL RESBEUT, M.D.,^{†††}
ERIC TEISSIER, M.D.,^{†††} PHILIPPE RONCHIN, M.D.,[‡] DIDIER COWEN, M.D.,^{§††} AUDREY ZACCARIOTTO, M.D.,[§]
KAREN BÉNÉZERY, M.D.,^{*} ERIC FRANÇOIS, M.D.,^{*} NAJI SALEM, M.D.,^{¶††} STEVE ELLIS, M.D.,^{||††}
DAVID AZRIA, M.D., PH.D.,^{**††} AND JEAN-PIERRE GERARD, M.D.,^{*}

^{*}Antoine Lacassagne Cancer Center, Nice; [†]French Red Cross, Toulon; [‡]Azurean Cancer Center, Mougins; [§]Timone Academic Hospital and [¶]Paoli Calmette Institut, Marseille; ^{||}Catalan Oncology Center, Perpignan; ^{**}Val d'Aurelle Cancer Center, Montpellier, and ^{††}Cercle des Oncologues Radiothérapeutes du Sud (C.O.R.S.), Mougins, France




- Hannoun-Levi JM, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, Zaccariotto A, Bénézery K, François E, Salem N, Ellis S, Azria D, Gerard JP. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). *Int J Radiat Oncol Biol Phys.* 2011

Boost: ERT o BT

Factors	Categories	5-year OS		5-year CRLR		5-year CFS	
		%	<i>P</i> value	%	<i>P</i> value	%	<i>P</i> value
Gender	Male	67	0.16	21	0.95	67	0.60
	Female	82		20		82	
Age	< 67 years	82	0.32	27	0.22	70	0.13
	≥ 67 years	75		25		60	
T stage	T1–2	84	0.009	15	0.03	72	0.04
	T3–4	68		36		51	
Nodal status	N0–1	83	<0.001	19	0.07	72	0.02
	N2–3	45		28		46	
Boost technique	BCT	78	0.47	12	0.002	71	0.04
	EBRT	80	–	33		56	
OTT	< 80	84	<0.001	14	0.005	74	0.004
	≥ 80	67		34		50	

Abbreviations: OS = overall free survival; CRLR = cumulated rate of local recurrence; CFS = colostomy-free survival; OTT = overall treatment time.



Conclusion: In anal cancer, when OTT is <80 days, BCT boost is superior to EBRT boost for CRLR. These results suggest investigating the benefit of BCT boost in prospective trials. © 2010 Elsevier Inc.

Boost: ERT o BT

International Journal of
Radiation Oncology
biology • physics

www.redjournal.org



Clinical Investigation: Gastrointestinal Cancer

Role of Brachytherapy in the Boost Management of Anal Carcinoma With Node Involvement (CORS-03 Study)

Laurence Moureau-Zabotto, MD,* Cecile Ortholan, MD, PhD,[†]
Jean-Michel Hannoun-Levi, MD, PhD,[‡] Eric Teissier, MD,[§] Didier Cowen, MD, PhD,^{||,¶}
Nagi Salem, MD,* Claire Lemanski, MD,[#] Steve Ellis, MD,** and Michel Resbeut, MD*·**

- Moureau-Zabotto L, Ortholan C, Hannoun-Levi JM, Teissier E, Cowen D, Salem N, Lemanski C, Ellis S, Resbeut M. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study) - *Int J Radiat Oncol Biol Phys.* 2013

Boost: ERT o BT



Conclusion: In anal cancer, even in the case of initial perirectal node invasion, BCT boost is superior to EBRT boost for CRLR, without an influence on OS, suggesting that N1 status should not be a contraindication to use of a BCT boost technique, as well as emphasizing the important of investigating the benefit of BCT boost in prospective randomized trials. © 2013 Elsevier Inc.

Boost ERT o BT: Tossicità



Conclusions: These results question the benefit of a radiotherapy boost after a 6-week gap. The higher doses of a boost may contribute more to an increased risk of late morbidity, rather than local control. © 2010 Elsevier Inc.



- Glynne-Jones R, Sebag-Montefiore D, Adams R, McDonald A, Gollins S, James R, Northover JM, Meadows HM, Jitlal M; "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). **Int J Radiat Oncol Biol Phys.** 2011

Boost ERT o BT: Tossicità

577 pazienti - boost dopo 6 settimane: EBRT (15 Gy) or iridium-192 implant (25 Gy)

ULCERA/RADIONECCROSI

BOOST

8%

NO BOOST

0%

p=0.03

ULCERA/RADIONECCROSI

BT BOOST

14%

ERT BOOST

6%

p=0.003

Brachiterapia LDR

- **Papillion et al.**

- *221 pazienti*
- *RT/CT (5-Fu + MMC) → BT-LDR (15-20Gy)*
- *5-years LC: 61% - 5-years SVV: 65%*
- *Funzione anale conservata: 90%*



- **Berger et al.**


- *69 pazienti*
- *RT o RT/TC (5-Fu + MMC) (40Gy) → BT-LDR (20Gy)*
- *5-years LC: 59%*
- *5-Years Colostomy rate: 33%*

Moderna Brachiterapia


IMBT
Intensity Modulated
BrachyTherapy



ABT
Adapted
BrachyTherapy



IGBT
Image Guided
BrachyTherapy



IABT
Image Adapted
BrachyTherapy



US guided-BT

Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy

J. M. Doniec,^{1*} B. Schniewind,^{1*} G. Kovács,² V. Kahlke,¹ M. Loehnert,³ B. Kremer¹

¹ Clinic for General and Thoracic Surgery, University Clinic of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 7, 24105 Kiel, Germany



² Interdisciplinary Center of Brachytherapy and Clinic of Radiation Therapy, University Clinic of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 7, 24105 Kiel, Germany

³ Städtisches Klinikum Bielefeld Rosenhöhe, An der Rosenhöhe 27, 33647 Bielefeld, Germany



- Doniec JM, Schniewind B, Kovács G, Kahlke V, Loehnert M, Kremer B. - Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. **Surg Endosc.** 2006

US guided-BT



no stenosi anali o rettali – 6% incontinenza anale

US guided-BT

IMAGE GUIDED BRACHYTHERAPY

+

STEPPING SOURCE



**IMPROVE LOCAL CONTROL
AND MINIMIZE MORBIDITY**

- Doniec JM, Schniewind B, Kovács G, Kahlke V, Loehnert M, Kremer B. - Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. **Surg Endosc. 2006**



MRI vs US

MRI offre maggiori informazioni:

- Contrasto e risoluzione spaziale
- dimensioni del tumore
- estensione e l'infiltrazione locale
- l'invasione di organi adiacenti
- Impianto multi-planare




- Goh V, Gollub FK, Liaw J, et al. Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? **Int J Radiat Oncol Biol Phys** 2010
- Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D. - Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. - **Radiother Oncol.** 2014

MR-guided BT



- La brachiterapia RM-guidata (RM-GBT) nel tumore del canale anale: studio preliminare dosimetrico e clinico - L. Tagliaferri, S. Manfrida, G.C. Mattiucci, M.M. Colangione, V. Masiello, S. Luzi, D. Smaniotto, B. Barbaro, A. Larghi, V. Valentini – Università Cattolica S. C. – Roma - **Congresso AIRO 2013**

MR-guided BT



- La brachiterapia RM-guidata (RM-GBT) nel tumore del canale anale: studio preliminare dosimetrico e clinico - L. Tagliaferri, S. Manfrida, G.C. Mattiucci, M.M. Colangione, V. Masiello, S. Luzi, D. Smaniotto, B. Barbaro, A. Larghi, V. Valentini – Università Cattolica S. C. – Roma - **Congresso AIRO 2013**

MR-guided BT

- Da 2/2012 a 7/2014: 9 pz
- Tutti i pz hanno effettuato la BT come boost dopo RT/CT
- Nessuna complicazione durante la procedura
- Buona compliance del paziente alla procedura
- La percentuale media di CTV coperta da meno del 100% della dose è stata del 4,9%

Prescrizione

LDR or PDR

- Sola BT: 60Gy at 0.5 Gy/h
- Boost BT (CT) EBRT (45-50Gy): 15-30 Gy at 0.5Gy/h

HDR

- Sola BT: 30-36Gy in 5-6 fx
- Boost BT (CT) EBRT (45-50Gy): 8-16.5 Gy in 2-3 fx

Controindicazioni

- *Tumore supera la metà della circonferenza*
- *Tumore supera 10 mm di spessore*
- *Tumore supera 5 cm di lunghezza cranio-caudale*
- *Controindicazioni all'anestesia*



Conclusioni

- Nel carcinoma del canale anale il controllo locale è correlato con una maggiore sopravvivenza e con una maggiore qualità di vita (assenza di colostomia)
- La brachiterapia può essere presa in considerazione per un dose-escalation al fine di aumentare il controllo locale
- Un minor OTT migliora i risultati clinici.

Conclusioni

- La BT determina una maggiore tossicità locale rispetto alla ERT (ulcera necrotica) ma IABT migliora il controllo locale e riduce la tossicità rispetto all'uso delle "sorgenti lineari"
- La BT interstiziale è equipe dipendente (Radioterapista-Fisico-Infermiere) per questo motivo dovrebbe essere eseguita in centri con un elevato numero di casi

**UN BOOST BT È RACCOMANDATO SE NON VI SONO CONTROINDICAZIONI
E SE IL PAZIENTE È TRATTATO IN UN CENTRO CON ESPERIENZA IN IABT,
SOPRATTUTTO IN PRESENZA DI UNA SCARSA RISPOSTA AL TRATTAMENTO**